会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 22. 发明公开
    • 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신
    • 来自肿瘤组织的纳米囊和使用相同的肿瘤疫苗
    • KR1020120132183A
    • 2012-12-05
    • KR1020110050854
    • 2011-05-27
    • 포항공과대학교 산학협력단
    • 고용송김윤근이은영장수철
    • A61K9/127A61K45/06A61K47/40A61K39/00
    • A61K39/0011A61K9/127A61K38/1709A61K47/10A61K47/40A61K2039/55561A61K39/0005A61K45/06A61K2121/00
    • PURPOSE: A pharmaceutical composition containing nanovesicles derived from tumor tissue and a method for treating cancer using the same are provided to enable shape changing of a nanovesicle antigen into various forms and to develop a cancer therapeutic vaccine. CONSTITUTION: A pharmaceutical composition for treating cancer contains nanovesicles derived from a tumor tissue. The tumor tissue is autologously derived from a patient with tumor or is prepared by transformation to express heat shock protein. The composition additionally contains an immunoadjuvant, polyI:C. The membrane of the nanovesicle contains cyclodextrin or polyethylene glycol. A method for preparing the nanovesicle comprises: a step of separating cells from the tumor tissue; a step of performing extrusion, sonication, cell lysis, homogenization, freezing-thawing, electroporation, mechanical lysis, or chemical treatment of a tumor cell suspension and preparing nanovesicles; a step of separating the nanovesicles from the suspension; and a step of adding the immunoadjuvant and culturing. A cancer vaccine contains a nanovesicle antigen derived from the tumor tissue.
    • 目的:提供含有源自肿瘤组织的纳米囊的药物组合物和使用其的治疗癌症的方法,以使纳米级抗原形状变化成各种形式并开发癌症治疗性疫苗。 构成:用于治疗癌症的药物组合物含有衍生自肿瘤组织的纳米囊。 肿瘤组织自体衍生自患有肿瘤的患者,或通过转化来表达热休克蛋白来制备。 组合物另外含有免疫佐剂,polyI:C。 纳米囊的膜含有环糊精或聚乙二醇。 制备纳米囊的方法包括:从肿瘤组织分离细胞的步骤; 进行挤出,超声处理,细胞裂解,均质化,冻融,电穿孔,机械裂解或化学处理肿瘤细胞悬浮液并制备纳米囊泡的步骤; 从悬浮液中分离纳米囊泡的步骤; 并添加免疫佐剂和培养的步骤。 癌症疫苗含有衍生自肿瘤组织的纳米级抗原。
    • 23. 发明公开
    • 체액 내 세포밖 소포체의 단백질 또는 유전자 분석을 통한 염증성 질환 진단 방법
    • 通过分析蛋白质或体液中的细胞外基质的方法来诊断炎症疾病
    • KR1020120111788A
    • 2012-10-11
    • KR1020110029195
    • 2011-03-31
    • 포항공과대학교 산학협력단
    • 고용송김윤근최은정윤예진장수철
    • G01N33/68C12Q1/68C12N15/12
    • G01N33/6827C12Q1/68C12Q2600/158G01N33/5302G01N33/6893
    • PURPOSE: A method for diagnosing inflammatory diseases and a diagnosis kit are provided to improve diagnosis accuracy. CONSTITUTION: A method for diagnosing inflammatory diseases comprises: a step of isolating cell adhesion proteins in fluid into water soluble protein fraction and extracellular endoplasmic reticulum fraction; and a step of quantitating proteins in the water soluble protein fraction and extracellular endoplasmic reticulum fraction. The proteins contain ICAM-1(intercellular adhesion molecule-1), E-selectin, and VCAM-1(vascular cell adhesion molecule-1). A method for diagnosing inflammatory diseases comprises a step of measuring the expression level of gene existing in the extracellular endoplasmic reticulum of body fluid. The cell adhesion protein is ICAM-1, E-selectin, and VCAM-1. [Reference numerals] (AA,EE) Cell culture liquid; (BB) Ultracentrifugation; (CC,FF) Soluble protein; (DD,GG) Extracellular endoplasmic reticulum
    • 目的:提供诊断炎性疾病的方法和诊断试剂盒,以提高诊断准确性。 构成:用于诊断炎性疾病的方法包括:将流体中的细胞粘附蛋白分离成水溶性蛋白质级分和细胞外质网层级的步骤; 以及定量水溶性蛋白质级分和细胞外质网层级蛋白质的步骤。 蛋白质含有ICAM-1(细胞间粘附分子-1),E-选择蛋白和VCAM-1(血管细胞粘附分子-1)。 用于诊断炎性疾病的方法包括测量存在于体液的细胞外质网中的基因的表达水平的步骤。 细胞粘附蛋白是ICAM-1,E-选择蛋白和VCAM-1。 (标号)(AA,EE)细胞培养液; (BB)超速离心; (CC,FF)可溶性蛋白; (DD,GG)细胞外质网
    • 30. 发明公开
    • 배아줄기세포 유래의 인공 마이크로베시클을 이용한 역분화 유도만능줄기세포의 제조방법
    • 使用衍生自胚胎干细胞的微泡制备诱导性多能干细胞的方法
    • KR1020120123624A
    • 2012-11-09
    • KR1020110040202
    • 2011-04-28
    • 포항공과대학교 산학협력단
    • 박재성고용송김윤근김준호장수철이남우정다영최은정
    • C12N5/074A61K35/545
    • C12N5/0696A61K35/545C12N2502/02C12N2506/13
    • PURPOSE: A method for preparing induced pluripotent stem cells by treating a composition containing a microvesicle is provided to develop cell therapeutic agent. CONSTITUTION: A method for preparing induced pluripotent stem cells comprises a step of treating somatic cells with a composition containing embryonic stem cell-derived microvesicle. The embryonic stem cells are derived from human or non-human primates, mouse, rat, dog, cat, house, or horse. The microvesicle additionally contains components except for a cell membrane of embryonic stem cells. The components are cyclodextrin or polyethylene glycol. The composition additionally contains a component except for the microvesicle, such as BFA(brefeldin A), BIX(BiP inducer X), or VPA(valproic acid). A cell therapeutic agent contains the induced pluripotent stem cells. [Reference numerals] (AA) Embryonic stem cell; (BB) Microvesicle
    • 目的:提供一种通过处理含有微泡的组合物制备诱导性多能干细胞的方法,以开发细胞治疗剂。 构成:用于制备诱导性多能干细胞的方法包括用含有胚胎干细胞衍生的微泡的组合物处理体细胞的步骤。 胚胎干细胞衍生自人或非人灵长类动物,小鼠,大鼠,狗,猫,家或马。 微泡除了胚胎干细胞的细胞膜外,还含有成分。 组分是环糊精或聚乙二醇。 该组合物另外含有除了微泡之外的组分,例如BFA(布雷菲德菌素A),BIX(BiP诱导剂X)或VPA(丙戊酸))。 细胞治疗剂含有诱导的多能干细胞。 (附图标记)(AA)胚胎干细胞; (BB)微囊泡